← Back to Clinical Trials
Recruiting NCT06923501

NCT06923501 Evaluation of a Mobile App Program for Coping With Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06923501
Status Recruiting
Phase
Sponsor Yale University
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-06-11
Primary Completion 2027-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Tools for Coping with Cancer Calm Health mobile app program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-06-11 with a primary completion date of 2027-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if a mobile app program for people with a history of cancer can help treat distress. The main questions it aims to answer is: Do participants use the Tools for Coping with Cancer Calm Health mobile app and do they find it helpful? Does the Tools for Coping with Cancer Calm Health mobile app improve mood, quality of life, and help with coping? Participants will be asked to use a 13-session self-management program (Tools for Coping with Cancer) housed within the Calm Health app. Participants will use this app on their own device, in their own home. Participants will have access to the program for 8 weeks and will be asked to work their way through the program at their own pace. Participants will be asked to complete questionnaires about their mood, quality of life, coping, and experience with the app three times: at the start of the study, after 8 weeks using the app, and then 3-months after using the app.

Eligibility Criteria

Inclusion Criteria: * Stated willingness to comply with all study procedures and availability for the duration of the study (8 weeks active intervention and 3-month follow up) * Have a confirmed diagnosis of cancer; or have been treated for cancer within the last two years, including adjuvant therapies * Over the age of 18 * Able to understand and read English * Able to navigate a mobile app with minimal assistance from study staff * Able to provide informed consent Exclusion Criteria: * Are taking part in psychotherapy at any time during the study * Have an un-treated or under-treated mental health disorder based on pre-study screening that may require a referral to individual mental health care.

Contact & Investigator

Central Contact

Gabriel Cartagena, PhD

✉ gabriel.cartagena@yale.edu

📞 516-855-8539

Principal Investigator

Gabriel Cartagena, PhD

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT06923501 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06923501 currently recruiting?

Yes, NCT06923501 is actively recruiting participants. Contact the research team at gabriel.cartagena@yale.edu for enrollment information.

Where is the NCT06923501 trial being conducted?

This trial is being conducted at New Haven, United States.

Who is sponsoring the NCT06923501 clinical trial?

NCT06923501 is sponsored by Yale University. The principal investigator is Gabriel Cartagena, PhD at Yale University. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology